Pangaea OncologyXMAD:PANG 63 Market Cap is €54.23 Mil as of Jul. 04, 2026. GuruFocus rates XMAD:PANG with a GF Score™ of 63/100 and a GF Value™ of €2.15 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 218 Medical Diagnostics & Research companies, Pangaea Oncology ranks better than 50.92% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Pangaea Oncology's share price for the quarter that ended in Dec. 2025 was €1.73. Pangaea Oncology's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 35.91 Mil. Therefore, Pangaea Oncology's market cap for the quarter that ended in Dec. 2025 was €62.13 Mil.
Pangaea Oncology's quarterly market cap
declined
from Dec. 2024 (€60.43 Mil) to Jun. 2025 (€57.69 Mil) but then
increased
from Jun. 2025 (€57.69 Mil) to Dec. 2025 (€62.13 Mil).
Pangaea Oncology's annual market cap
increased
from Dec. 2023 (€44.31 Mil) to Dec. 2024 (€60.43 Mil) and
increased
from Dec. 2024 (€60.43 Mil) to Dec. 2025 (€62.13 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Pangaea Oncology's Enterprise Value for Today is €57.74 Mil.
Pangaea Oncology (XMAD:PANG) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Pangaea Oncology Market Cap Related Terms
Pangaea Oncology Market Cap Historical Data
* Premium members only.
The historical data trend for Pangaea Oncology's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:PANG vs TMO, DHR, IDXX: Market Cap Comparison
For the Diagnostics & Research subindustry, Pangaea Oncology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pangaea Oncology Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pangaea Oncology's Market Cap distribution charts can be found below:
* The bar in red indicates where Pangaea Oncology's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Pangaea Oncology's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pangaea Oncology (XMAD:PANG) has a Market Cap of €54.23 Mil as of Jul. 04, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Pangaea Oncology and its competitors. According to the industry distribution chart, Pangaea Oncology ranks #107 out of 218 companies in the Medical Diagnostics & Research industry, placing it in the top 49.1%.
Is Pangaea Oncology's Market Cap too high?
Pangaea Oncology's current Market Cap is €54.23 Mil. Based on the distribution chart, Pangaea Oncology ranks #107 out of 218 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Pangaea Oncology has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's Market Cap compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pangaea Oncology ranks #107 out of 218 companies for Market Cap. This puts Pangaea Oncology in the upper half of its industry. The industry median Market Cap is 58.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 58.14, based on 218 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Pangaea Oncology and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 58.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pangaea Oncology's current Market Cap is €54.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Possible Value Trap. The stock's GF Value™ is €2.15, compared to a current price of €1.51 — trading 29.8% below its estimated fair value. The current Market Cap is €54.23 Mil. Pangaea Oncology's overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current Market Cap is €54.23 Mil as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?
Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued.
The current stock price of €1.51 is trading 29.8% below its estimated GF Value™ of €2.15.
GuruFocus considers Pangaea Oncology to be Possible Value Trap.
Key valuation signals for XMAD:PANG:
Market Cap: €54.23 Mil
GF Value™: €2.15 vs. price of €1.51 (29.8% below fair value)
No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
63GF Score
Get the complete analysis for XMAD:PANG
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PANG has been successfully added to your 
